Full Text Journal Articles in
Journal Lancet Diabetes Endocrinol

Advertisement

Find full text journal articles






EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.

Vanita R Aroda, Marc S Sabatine,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):932-933]

Cited: 0 times

View full text PDF listing >>



Correction to Lancet Diabetes Endocrinol 2016; 4: 732-33.

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):e7]

Cited: 0 times

View full text PDF listing >>



Advertisement

Correction to Lancet Diabetes Endocrinol 2020; 8: 939-48.

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):e7]

Cited: 0 times

View full text PDF listing >>



Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations.

Karel Pacak, David Taieb,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.

Darren K McGuire, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, David Fitchett, Stefan D Anker, Stuart Pocock, Stefan Kaspers, Jyothis T George, Maximilian von Eynatten, Odd Erik Johansen, Waheed Jamal, Michaela Mattheus, Ulrich Elsasser, Stefan Hantel, Søren S Lund,

BACKGROUND:Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in the EMPA-REG OUTCOME trial. METHODS:The EMPA-REG OUTCOME trial was a randomised, double-blind, non-inferiority trial of patients (aged ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):949-959]

Cited: 0 times

View full text PDF listing >>



Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature.

Irina Bancos, Elizabeth Atkinson, Charis Eng, William F Young, Hartmut P H Neumann, ,

BACKGROUND:Phaeochromocytoma or paraganglioma (collectively known as PPGL) in pregnant women can lead to severe complications and death due to associated catecholamine excess. We aimed to identify factors associated with maternal and fetal outcomes in women with PPGL during pregnancy. METHODS:We did a multicentre, retrospective study of patients with PPGL and ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Diabetes, metabolic disease, and telomere length.

Feifei Cheng, Luke Carroll, Mugdha V Joglekar, Andrzej S Januszewski, Kwun Kiu Wong, Anandwardhan A Hardikar, Alicia J Jenkins, Ronald C W Ma,

Telomeres are regions of repetitive nucleotide sequences at the ends of chromosomes. Telomere length is a marker of DNA damage, which is often considered a biomarker for biological ageing, and has also been linked with cardiovascular disease, diabetes, and cancer. Emerging studies have highlighted the role of genetic and environmental ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Global 30-day outcomes after bariatric surgery during the COVID-19 pandemic (GENEVA): an international cohort study.

Rishi Singhal, Abd A Tahrani, Christian Ludwig, Kamal Mahawar, ,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Skin-whitening creams: worth the risk?

Talha Burki,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Thyroid cancer in the USA: current trends and outstanding questions.

Louise Davies, Jenny K Hoang,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Nurses: at the heart of diabetes care.

The Lancet Diabetes Endocrinology,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):931]

Cited: 0 times

View full text PDF listing >>



Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.

Nikolaus Marx, Melanie J Davies, Peter J Grant, Chantal Mathieu, John R Petrie, Francesco Cosentino, John B Buse,

Cardiovascular outcome trials in patients with type 2 diabetes at high cardiovascular risk have led to remarkable advances in our understanding of the effectiveness of GLP-1 receptor agonists and SGLT2 inhibitors to reduce cardiorenal events. In 2019, the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Correction to Lancet Diabetes Endocrinol 2020; 8: 782-92.

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):e6]

Cited: 0 times

View full text PDF listing >>



Bone mineral density as a surrogate biomarker for fracture risk reduction - Authors' reply.

Dennis M Black, Mary L Bouxsein, Douglas C Bauer, Richard Eastell,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):876]

Cited: 0 times

View full text PDF listing >>



Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.

Megumi Oshima, Brendon L Neuen, Meg J Jardine, George Bakris, Robert Edwards, Adeera Levin, Kenneth W Mahaffey, Bruce Neal, Carol Pollock, Norman Rosenthal, Takashi Wada, David C Wheeler, Vlado Perkovic, Hiddo J L Heerspink,

BACKGROUND:Sodium-glucose co-transporter 2 inhibitors might enhance erythropoiesis and increase red blood cell mass. We assessed the long-term effects of canagliflozin on anaemia-related outcomes. METHODS:In a post-hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, we included patients with type 2 diabetes and ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):903-914]

Cited: 0 times

View full text PDF listing >>



Bone mineral density as a surrogate biomarker for fracture risk reduction.

Josivan G Lima, Lucia H C Nóbrega, Marcel C F Santos, Breno C C Simas,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):875-876]

Cited: 0 times

View full text PDF listing >>



Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study.

Andreas Ebbehoj, Dingfeng Li, Ravinder J Kaur, Catherine Zhang, Sumitabh Singh, Taoran Li, Elizabeth Atkinson, Sara Achenbach, Sundeep Khosla, Wiebke Arlt, William F Young, Walter A Rocca, Irina Bancos,

BACKGROUND:Adrenal tumours are commonly encountered in clinical practice, but epidemiological data mainly originate from referral centres. We aimed to determine incidence, prevalence, and rates of malignancy and hormone excess in patients with adrenal tumours in a standardised geographically well defined population. METHODS:In this retrospective population-based cohort study we assessed the ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):894-902]

Cited: 0 times

View full text PDF listing >>



Bone mineral density as a surrogate biomarker for fracture risk reduction.

Viral N Shah,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):875]

Cited: 0 times

View full text PDF listing >>



Metabolic health in Brazil: trends and challenges.

Ricardo V Cohen, Luciano F Drager, Tarissa B Z Petry, Raul D Santos,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):937-938]

Cited: 0 times

View full text PDF listing >>



Urine metabolomic phenotyping for detection of adrenocortical carcinoma: still a long way to go - Authors' reply.

Irina Bancos, Angela E Taylor, Vasileios Chortis, Alice J Sitch, Katharina Lang, Alessandro Prete, Lorna C Gilligan, Michael Biehl, Jonathan J Deeks, Wiebke Arlt, ,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):877-878]

Cited: 0 times

View full text PDF listing >>



Understanding the epidemiology of adrenal tumours.

Quan-Yang Duh,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):871-873]

Cited: 0 times

View full text PDF listing >>



Setmelanotide: what does it mean for clinical care of patients with obesity?

Donna H Ryan,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):933-935]

Cited: 0 times

View full text PDF listing >>



Correction to Lancet Diabetes Endocrinol 2020; 8: 834-44.

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):e6]

Cited: 0 times

View full text PDF listing >>



Urine metabolomic phenotyping for detection of adrenocortical carcinoma: still a long way to go.

Panagiota Anyfanti, Barbara Nikolaidou, Eugenia Gkaliagkousi,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(11):876-877]

Cited: 0 times

View full text PDF listing >>



Insulin's centenary: the birth of an idea.

Robert A Hegele, Grant M Maltman,

At 2:00 h on Oct 31, 1920, Frederick G Banting, a surgeon practising in London, ON, Canada, conceived an idea to isolate the internal secretion of the pancreas. The following week, he met with noted scientist John J R Macleod in Toronto, ON, Canada, and they developed a research plan. ... Read more >>

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):971-977]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
0.8962 s